Cell cycle effects of gemcitabine

Paolo Cappella, Daniela Tomasoni, Mario Faretta, Monica Lupi, Francesco Montalenti, Federica Viale, Fabio Banzato, Maurizio D'Incalci, Paolo Ubezio

Research output: Contribution to journalArticle

Abstract

Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, or dFdC) is a promising anticancer agent with demonstrated clinical activity in solid tumours currently undergoing clinical trials. Despite extensive studies on the biochemical mechanism of action, cell cycle perturbations induced by dFdC have not yet been thoroughly investigated, apart from the expected inhibition of DNA synthesis. The aim of our study was to clarify whether cell population kinetics is a vital factor in the cytotoxicity of dFdC in single or repeated treatments and in the dFdC-cisplatin combination. Ovarian cancer cells growing in vitro were treated with dFdC for I hr in a range of concentrations from 10 nM to 10 μM. Cell kinetics was investigated by DNA-bromodeoxyuridine flow cytometry, using different experimental protocols to measure either the time course of DNA-synthesis inhibition or the fate of cells in G1, S or G2M at the time of dFdC treatment or 24 hr later. A modified sulforhodamine B test was used to assess the growth inhibition caused by dFdC given alone or with cisplatin. Although dFdC promptly inhibited DNA synthesis, cytotoxicity on proliferating cells was not specific for cells initially in the S phase. DNA synthesis was restored after a G block of variable, dose-dependent length, but recycling ce Is were intercepted at the subsequent checkpoints, resulting in delays in the G2M and G1 phases. The activity of repeated treatment with dFdC+dFdC or dFdC+cisplatin was highly dependent on the interval length between them. These results suggest that the kinetics of cell recycling from a first dFdC treatment strongly affects the outcome of a second treatment with either dFdC itself or cisplatin.

Original languageEnglish
Pages (from-to)401-408
Number of pages8
JournalInternational Journal of Cancer
Volume93
Issue number3
DOIs
Publication statusPublished - Aug 1 2001

Fingerprint

gemcitabine
Cell Cycle
Cisplatin
DNA
lissamine rhodamine B
Deoxycytidine
G1 Phase
Recycling
Bromodeoxyuridine
S Phase
Antineoplastic Agents
Ovarian Neoplasms
Flow Cytometry
Clinical Trials

Keywords

  • Apoptosis
  • Cell cycle
  • Cell proliferation
  • Chemotherapy
  • Flow cytometry
  • Gemcitabine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cell cycle effects of gemcitabine. / Cappella, Paolo; Tomasoni, Daniela; Faretta, Mario; Lupi, Monica; Montalenti, Francesco; Viale, Federica; Banzato, Fabio; D'Incalci, Maurizio; Ubezio, Paolo.

In: International Journal of Cancer, Vol. 93, No. 3, 01.08.2001, p. 401-408.

Research output: Contribution to journalArticle

Cappella, P, Tomasoni, D, Faretta, M, Lupi, M, Montalenti, F, Viale, F, Banzato, F, D'Incalci, M & Ubezio, P 2001, 'Cell cycle effects of gemcitabine', International Journal of Cancer, vol. 93, no. 3, pp. 401-408. https://doi.org/10.1002/ijc.1351
Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F et al. Cell cycle effects of gemcitabine. International Journal of Cancer. 2001 Aug 1;93(3):401-408. https://doi.org/10.1002/ijc.1351
Cappella, Paolo ; Tomasoni, Daniela ; Faretta, Mario ; Lupi, Monica ; Montalenti, Francesco ; Viale, Federica ; Banzato, Fabio ; D'Incalci, Maurizio ; Ubezio, Paolo. / Cell cycle effects of gemcitabine. In: International Journal of Cancer. 2001 ; Vol. 93, No. 3. pp. 401-408.
@article{3e9b70744f8145b38089974fe4511c9e,
title = "Cell cycle effects of gemcitabine",
abstract = "Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, or dFdC) is a promising anticancer agent with demonstrated clinical activity in solid tumours currently undergoing clinical trials. Despite extensive studies on the biochemical mechanism of action, cell cycle perturbations induced by dFdC have not yet been thoroughly investigated, apart from the expected inhibition of DNA synthesis. The aim of our study was to clarify whether cell population kinetics is a vital factor in the cytotoxicity of dFdC in single or repeated treatments and in the dFdC-cisplatin combination. Ovarian cancer cells growing in vitro were treated with dFdC for I hr in a range of concentrations from 10 nM to 10 μM. Cell kinetics was investigated by DNA-bromodeoxyuridine flow cytometry, using different experimental protocols to measure either the time course of DNA-synthesis inhibition or the fate of cells in G1, S or G2M at the time of dFdC treatment or 24 hr later. A modified sulforhodamine B test was used to assess the growth inhibition caused by dFdC given alone or with cisplatin. Although dFdC promptly inhibited DNA synthesis, cytotoxicity on proliferating cells was not specific for cells initially in the S phase. DNA synthesis was restored after a G block of variable, dose-dependent length, but recycling ce Is were intercepted at the subsequent checkpoints, resulting in delays in the G2M and G1 phases. The activity of repeated treatment with dFdC+dFdC or dFdC+cisplatin was highly dependent on the interval length between them. These results suggest that the kinetics of cell recycling from a first dFdC treatment strongly affects the outcome of a second treatment with either dFdC itself or cisplatin.",
keywords = "Apoptosis, Cell cycle, Cell proliferation, Chemotherapy, Flow cytometry, Gemcitabine",
author = "Paolo Cappella and Daniela Tomasoni and Mario Faretta and Monica Lupi and Francesco Montalenti and Federica Viale and Fabio Banzato and Maurizio D'Incalci and Paolo Ubezio",
year = "2001",
month = "8",
day = "1",
doi = "10.1002/ijc.1351",
language = "English",
volume = "93",
pages = "401--408",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Cell cycle effects of gemcitabine

AU - Cappella, Paolo

AU - Tomasoni, Daniela

AU - Faretta, Mario

AU - Lupi, Monica

AU - Montalenti, Francesco

AU - Viale, Federica

AU - Banzato, Fabio

AU - D'Incalci, Maurizio

AU - Ubezio, Paolo

PY - 2001/8/1

Y1 - 2001/8/1

N2 - Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, or dFdC) is a promising anticancer agent with demonstrated clinical activity in solid tumours currently undergoing clinical trials. Despite extensive studies on the biochemical mechanism of action, cell cycle perturbations induced by dFdC have not yet been thoroughly investigated, apart from the expected inhibition of DNA synthesis. The aim of our study was to clarify whether cell population kinetics is a vital factor in the cytotoxicity of dFdC in single or repeated treatments and in the dFdC-cisplatin combination. Ovarian cancer cells growing in vitro were treated with dFdC for I hr in a range of concentrations from 10 nM to 10 μM. Cell kinetics was investigated by DNA-bromodeoxyuridine flow cytometry, using different experimental protocols to measure either the time course of DNA-synthesis inhibition or the fate of cells in G1, S or G2M at the time of dFdC treatment or 24 hr later. A modified sulforhodamine B test was used to assess the growth inhibition caused by dFdC given alone or with cisplatin. Although dFdC promptly inhibited DNA synthesis, cytotoxicity on proliferating cells was not specific for cells initially in the S phase. DNA synthesis was restored after a G block of variable, dose-dependent length, but recycling ce Is were intercepted at the subsequent checkpoints, resulting in delays in the G2M and G1 phases. The activity of repeated treatment with dFdC+dFdC or dFdC+cisplatin was highly dependent on the interval length between them. These results suggest that the kinetics of cell recycling from a first dFdC treatment strongly affects the outcome of a second treatment with either dFdC itself or cisplatin.

AB - Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, or dFdC) is a promising anticancer agent with demonstrated clinical activity in solid tumours currently undergoing clinical trials. Despite extensive studies on the biochemical mechanism of action, cell cycle perturbations induced by dFdC have not yet been thoroughly investigated, apart from the expected inhibition of DNA synthesis. The aim of our study was to clarify whether cell population kinetics is a vital factor in the cytotoxicity of dFdC in single or repeated treatments and in the dFdC-cisplatin combination. Ovarian cancer cells growing in vitro were treated with dFdC for I hr in a range of concentrations from 10 nM to 10 μM. Cell kinetics was investigated by DNA-bromodeoxyuridine flow cytometry, using different experimental protocols to measure either the time course of DNA-synthesis inhibition or the fate of cells in G1, S or G2M at the time of dFdC treatment or 24 hr later. A modified sulforhodamine B test was used to assess the growth inhibition caused by dFdC given alone or with cisplatin. Although dFdC promptly inhibited DNA synthesis, cytotoxicity on proliferating cells was not specific for cells initially in the S phase. DNA synthesis was restored after a G block of variable, dose-dependent length, but recycling ce Is were intercepted at the subsequent checkpoints, resulting in delays in the G2M and G1 phases. The activity of repeated treatment with dFdC+dFdC or dFdC+cisplatin was highly dependent on the interval length between them. These results suggest that the kinetics of cell recycling from a first dFdC treatment strongly affects the outcome of a second treatment with either dFdC itself or cisplatin.

KW - Apoptosis

KW - Cell cycle

KW - Cell proliferation

KW - Chemotherapy

KW - Flow cytometry

KW - Gemcitabine

UR - http://www.scopus.com/inward/record.url?scp=0035426936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035426936&partnerID=8YFLogxK

U2 - 10.1002/ijc.1351

DO - 10.1002/ijc.1351

M3 - Article

C2 - 11433406

AN - SCOPUS:0035426936

VL - 93

SP - 401

EP - 408

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -